{"generic":"Vemurafenib","drugs":["Vemurafenib","Zelboraf"],"mono":{"0":{"id":"929998-s-0","title":"Generic Names","mono":"Vemurafenib"},"1":{"id":"929998-s-1","title":"Dosing and Indications","sub":[{"id":"929998-s-1-4","title":"Adult Dosing","mono":"<ul><li>before starting vemurafenib, confirm presence of BRAF V600E mutation in tumor specimen, perform a dermatologic evaluation, and establish baseline monitoring of ECG, electrolytes, liver enzymes, and bilirubin<\/li><li><b>Malignant melanoma, Unresectable, stage IIIC or metastatic, BRAF V600E mutation positive:<\/b> 960 mg ORALLY every 12 hours; continue treatment until disease progression or unacceptable toxicity occurs<\/li><li><b>Malignant melanoma, Unresectable, stage IIIC or metastatic, BRAF V600E mutation positive:<\/b> if vomiting occurs, do not repeat dose<\/li><\/ul>"},{"id":"929998-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy of vemurafenib have not been established in pediatric patients younger than 18 years "},{"id":"929998-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>cutaneous malignancy, primary (new):<\/b> dose modifications are not recommended<\/li><li><b>grade 2 (intolerable) or grade 3 toxicities:<\/b> for first appearance, interrupt until grade 0 to 1, then resume at 720 mg every 12 hours; for second appearance, interrupt until grade 0 to 1, then resume at 480 mg twice daily; doses below 480 mg twice daily are not recommended<\/li><li><b>grade 4 toxicities:<\/b> for first appearance, discontinue permanently (if clinically appropriate) or interrupt treatment until grade 0 to 1 and resume dosing at 480 mg twice daily; for second appearance, discontinue permanently; doses below 480 mg twice daily are not recommended<\/li><li>hepatic impairment (mild and moderate); no dose adjustment needed<\/li><li><b>QT prolongation, exceeding 500 milliseconds (grade 3 toxicity):<\/b> correct electrolyte abnormalities, control cardiac risk factors for QT prolongation, and interrupt treatment until QTc is less than 500 milliseconds, then resume at a lower dose (doses below 480 mg twice daily are not recommended); if, after correction of associated risk factors, the QTc remains above 500 milliseconds and has increased more than 60 milliseconds above baseline values, then permanently discontinue vemurafenib<\/li><li>renal impairment (mild and moderate); no dose adjustment needed<\/li><\/ul>"},{"id":"929998-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Malignant melanoma, Unresectable, stage IIIC or metastatic, BRAF V600E mutation positive<br\/>"}]},"3":{"id":"929998-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929998-s-3-9","title":"Contraindications","mono":"Specific contraindications have not been determined <br\/>"},{"id":"929998-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- QT prolongation has been reported, with an increased risk in patients with QTc interval greater than 500 milliseconds or long QT syndrome (use not recommended); monitoring recommended and reduction of dose, interruption, or discontinuation may be necessary<\/li><li>-- Uncorrectable electrolyte abnormalities have increased risk for QT prolongation; not recommended<\/li><li>Dermatologic:<\/li><li>-- Cutaneous squamous cell carcinoma, including keratoacanthomas, has been reported, with an increased risk with age greater than 65 years, prior skin cancer, and chronic sun exposure; monitoring recommended<\/li><li>-- New primary malignant melanoma has been reported; monitoring recommended<\/li><li>-- Increased cell proliferation in BRAF wild-type cells has occurred with in vitro exposure to BRAF inhibitors; confirm BRAF V600E mutation status prior to initiation of treatment<\/li><li>-- Severe dermatologic reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported; discontinue<\/li><li>-- Mild to severe photosensitivity has been reported; dosage adjustment may be necessary<\/li><li>Hepatic:<\/li><li>-- Liver injury leading to functional hepatic impairment, coagulopathy, or other organ dysfunction may occur; monitoring recommended and reduction of dose, interruption, or discontinuation may be necessary<\/li><li>Immunologic:<\/li><li>-- Anaphylaxis and other severe hypersensitivity reactions (eg, drug reaction with eosinophilia and systemic symptoms, hypotension) may occur; discontinue use permanently if such reactions occur<\/li><li>Ophthalmic:<\/li><li>-- Ophthalmologic reactions (eg, uveitis, blurred vision, iritis, photophobia) have been reported and may require additional treatment; monitoring recommended<\/li><li>Other:<\/li><li>-- Noncutaneous, squamous cell carcinoma of the head and neck may occur; monitoring recommended<\/li><li>-- Malignancy associated with RAS activation may occur; monitoring recommended<\/li><li>Concomitant use:<\/li><li>-- Other agents known to prolong QT interval not recommended<\/li><li>-- Avoid strong CYP3A4 inhibitors or strong CYP3A4 inducers<\/li><li>-- Drugs predominantly metabolized by CYP1A2 that have a narrow therapeutic window not recommended<\/li><li>--The safety and efficacy with concomitant use of ipilimumab has not been established; significant elevations in liver transaminases and bilirubin have been observed in patients receiving this combination<\/li><\/ul>"},{"id":"929998-s-3-11","title":"Pregnancy Category","mono":"D (FDA)<br\/>"},{"id":"929998-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"929998-s-4","title":"Drug Interactions","sub":[{"id":"929998-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Levomethadyl (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Nelfinavir (theoretical)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"929998-s-4-14","title":"Major","mono":"<ul><li>Alfuzosin (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aprepitant (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Artemether (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Disopyramide (theoretical)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Doxepin (theoretical)<\/li><li>Droperidol (theoretical)<\/li><li>Ebastine (theoretical)<\/li><li>Elvitegravir (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Eribulin (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Famotidine (theoretical)<\/li><li>Felbamate (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Formoterol (theoretical)<\/li><li>Fosaprepitant (theoretical)<\/li><li>Foscarnet (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Galantamine (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydroquinidine (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Mizolastine (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Nefazodone (theoretical)<\/li><li>Nifedipine (probable)<\/li><li>Nilotinib (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Olanzapine (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Paroxetine (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pentamidine (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Perphenazine (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Probucol (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>Rilpivirine (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Tamoxifen (theoretical)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolterodine (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Trifluoperazine (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Venlafaxine (theoretical)<\/li><li>Vilanterol (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Vorinostat (theoretical)<\/li><\/ul>"},{"id":"929998-s-4-15","title":"Moderate","mono":"<ul><li>Dextromethorphan (probable)<\/li><li>Midazolam (probable)<\/li><li>Warfarin (probable)<\/li><\/ul>"}]},"5":{"id":"929998-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Alopecia (all grades, 36% to 45%; grade 3, less than 1%), Papilloma of skin (all grades, 21% to 30%; grade 3, less than 1%), Photosensitivity (all grades, 33% to 49%; grade 3, 3%), Pruritus (all grades, 23% to 30%; grade 3, 1% to 2%), Rash (all grades, 37% to 52%; grade 3, 7% to 8%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (all grades, 35% to 37%; grade 3, 2%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (all grades, 53% to 67%; grade 3, 4% to 8%)<\/li><li><b>Other:<\/b>Fatigue (all grades, 38% to 54%; grade 3, 2% to 4%), Papilloma of skin (all grades, 21% to 30%; grade 3, less than 1%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Prolonged QT interval<\/li><li><b>Dermatologic:<\/b>Hand-foot syndrome due to cytotoxic therapy (less than 10%), Keratoacanthoma, Malignant melanoma (2.1%), Squamous cell carcinoma of skin, Stevens-Johnson syndrome (less than 10%), Toxic epidermal necrolysis (less than 10%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Other:<\/b>Keratoacanthoma, Malignant melanoma (2.1%), Squamous cell carcinoma of skin<\/li><\/ul>"},"6":{"id":"929998-s-6","title":"Drug Name Info","sub":{"0":{"id":"929998-s-6-17","title":"US Trade Names","mono":"Zelboraf<br\/>"},"2":{"id":"929998-s-6-19","title":"Class","mono":"<ul><li>Antineoplastic Agent<\/li><li>BRAF Inhibitor<\/li><\/ul>"},"3":{"id":"929998-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929998-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929998-s-7","title":"Mechanism Of Action","mono":"Vemurafenib is a kinase inhibitor of some mutated forms of BRAF serine-threonine kinase, including BRAF V600E. Vemurafenib has displayed antitumor effects in cellular and animal models of melanomas with mutated BRAF V600E.<br\/>"},"8":{"id":"929998-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"929998-s-8-23","title":"Absorption","mono":"<ul><li>Tmax: 3 hours<\/li><li>Bioavailability: undetermined<\/li><li>Effect of food: increased AUC 5-fold, increased Cmax 2.5-fold, delayed Tmax 4 hours<\/li><\/ul>"},"1":{"id":"929998-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 106 L<\/li><li>Protein binding: greater than 99%<\/li><\/ul>"},"3":{"id":"929998-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 94%<\/li><li>Renal: 1%<\/li><li>Total body clearance: 31 L\/day<\/li><\/ul>"},"4":{"id":"929998-s-8-27","title":"Elimination Half Life","mono":"57 hours <br\/>"}}},"9":{"id":"929998-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>take with or without a meal<\/li><li>do not chew or crush<\/li><li>missed doses can be taken up to 4 hours prior to the next dose<\/li><\/ul>"},"10":{"id":"929998-s-10","title":"Monitoring","mono":"<ul><li>confirm BRAF V600E mutation-positive melanoma by an FDA-approved test (cobas(R) 4800 BRAF V600 Mutation Test); prior to treatment<\/li><li>evidence of tumor response indicates efficacy<\/li><li>electrolytes, including potassium, magnesium, and calcium; prior to and following initiation of therapy, after any dose modifications, 15 days after initiation, then monthly during the first 3 months, followed by every 3 months thereafter, or more often as clinically needed<\/li><li>liver enzymes (transaminases and alkaline phosphatase) and bilirubin; prior to initiation and monthly during treatment, or as clinically indicated<\/li><li>dermatological evaluations for new primary cutaneous malignancies; prior to initiation, every 2 months while on therapy, and consider monitoring 6 months after therapy discontinuation<\/li><li>signs and symptoms of new noncutaneous squamous cell carcinomas, particularly of the head and neck; prior to initiation of therapy and periodically during treatment<\/li><li>signs and symptoms of other malignancies, including those associated with RAS activation<\/li><li>ECG; prior to and following initiation of therapy, after any dose modifications, 15 days after initiation, then monthly during the first 3 months, followed by every 3 months thereafter, or more often as clinically needed<\/li><li>signs and symptoms of uveitis; routinely<\/li><\/ul>"},"11":{"id":"929998-s-11","title":"How Supplied","mono":"<b>Zelboraf<\/b><br\/>Oral Tablet: 240 MG<br\/>"},"13":{"id":"929998-s-13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to avoid sun exposure, wear protective clothing, and use a sunscreen as drug causes photosensitivity.<\/li><li>Advise patient to immediately report symptoms of severe dermatologic reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) or new cutaneous malignancies.<\/li><li>Side effects may include arthralgia, rash, alopecia, fatigue, nausea, pruritus, and skin papilloma.<\/li><li>Tell patient to report cardiac symptoms of QT prolongation.<\/li><li>Counsel patient to report vision changes, photophobia, or symptoms of uveitis.<\/li><\/ul>"}}}